newsfilter
← Latest News
Business Wire·

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

FDA established a PDUFA action date for ATI-1501 of September 23, 2023 Government funding committed to enable Appili to advance its biodefense vaccine candidate ATI-1701 towards an IND Appili Therapeutics Inc.